BioFocus and Argenta Announce Drug Discovery Collaboration with AstraZeneca in Respiratory and Inflammatory Disease
Galapagos’ service companies, BioFocus and Argenta, announced they have entered into a multi-year collaboration agreement with AstraZeneca to find new compounds against key targets of interest to AstraZeneca’s research programs in respiratory and inflammatory diseases.
Under the terms of the collaboration, each AstraZeneca project will engage the medicinal chemistry, biology and ADME/PK capabilities of either BioFocus or Argenta, and will also be able to access the full suite of in vivo respiratory pharmacology models which reside within Argenta.
Financial details were not disclosed.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.